Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Blood Pressure | 11 | 2019 | 2198 | 1.75 | Why? |
| Hypertension | 21 | 2021 | 8895 | 1.62 | Why? |
| Blood Pressure Determination | 5 | 2019 | 450 | 1.58 | Why? |
| Hypertrophy, Left Ventricular | 3 | 2019 | 219 | 1.35 | Why? |
| Antihypertensive Agents | 11 | 2021 | 1962 | 1.08 | Why? |
| Vascular Stiffness | 3 | 2019 | 264 | 0.89 | Why? |
| Ventricular Function, Left | 3 | 2018 | 1555 | 0.85 | Why? |
| Nocturia | 1 | 2018 | 8 | 0.78 | Why? |
| Intracranial Hemorrhage, Hypertensive | 1 | 2018 | 4 | 0.76 | Why? |
| Vascular Remodeling | 1 | 2019 | 99 | 0.75 | Why? |
| Carotid Artery Diseases | 2 | 2018 | 251 | 0.70 | Why? |
| Ventricular Remodeling | 2 | 2018 | 349 | 0.70 | Why? |
| Microcirculation | 2 | 2019 | 447 | 0.63 | Why? |
| Microvessels | 1 | 2019 | 490 | 0.56 | Why? |
| Pulse Wave Analysis | 3 | 2019 | 221 | 0.52 | Why? |
| Cardiovascular Agents | 2 | 2017 | 663 | 0.45 | Why? |
| Foramen Ovale, Patent | 1 | 2013 | 153 | 0.41 | Why? |
| Ventricular Dysfunction, Left | 1 | 2018 | 993 | 0.39 | Why? |
| Renal Insufficiency, Chronic | 3 | 2021 | 2654 | 0.36 | Why? |
| Carotid Intima-Media Thickness | 2 | 2019 | 179 | 0.35 | Why? |
| Hypertension, Malignant | 1 | 2006 | 3 | 0.33 | Why? |
| Carotid Arteries | 2 | 2019 | 182 | 0.33 | Why? |
| Emergency Service, Hospital | 3 | 2020 | 14232 | 0.27 | Why? |
| Kidney | 1 | 2018 | 3648 | 0.26 | Why? |
| Heart Failure | 4 | 2021 | 6638 | 0.25 | Why? |
| Retinal Vessels | 1 | 2006 | 255 | 0.25 | Why? |
| Aging | 1 | 2019 | 3581 | 0.24 | Why? |
| Arterial Pressure | 2 | 2021 | 208 | 0.23 | Why? |
| Chlamydophila pneumoniae | 1 | 2021 | 98 | 0.21 | Why? |
| Cardiovascular Diseases | 4 | 2020 | 11497 | 0.21 | Why? |
| Risk Factors | 14 | 2021 | 71621 | 0.19 | Why? |
| Antibodies, Anticardiolipin | 1 | 2020 | 208 | 0.19 | Why? |
| Hyperaldosteronism | 1 | 2018 | 17 | 0.19 | Why? |
| Retinal Artery | 1 | 2018 | 16 | 0.18 | Why? |
| Italy | 14 | 2021 | 38444 | 0.18 | Why? |
| Heart Rupture | 1 | 2018 | 14 | 0.18 | Why? |
| Adrenalectomy | 1 | 2018 | 32 | 0.18 | Why? |
| Vascular Resistance | 1 | 2019 | 148 | 0.18 | Why? |
| Stroke | 2 | 2020 | 8839 | 0.18 | Why? |
| Pneumonia, Mycoplasma | 1 | 2021 | 292 | 0.17 | Why? |
| Recovery of Function | 2 | 2018 | 2461 | 0.17 | Why? |
| Dihydropyridines | 1 | 2017 | 29 | 0.17 | Why? |
| Hydrochlorothiazide | 1 | 2017 | 31 | 0.17 | Why? |
| Renin-Angiotensin System | 4 | 2021 | 3661 | 0.17 | Why? |
| Pulmonary Embolism | 2 | 2017 | 4775 | 0.17 | Why? |
| Cocaine-Related Disorders | 1 | 2018 | 51 | 0.17 | Why? |
| Enalapril | 1 | 2017 | 54 | 0.17 | Why? |
| Albuminuria | 1 | 2018 | 164 | 0.17 | Why? |
| Blood Pressure Monitoring, Ambulatory | 1 | 2019 | 341 | 0.15 | Why? |
| Myocardial Contraction | 1 | 2017 | 123 | 0.15 | Why? |
| Peripheral Vascular Diseases | 1 | 2017 | 133 | 0.15 | Why? |
| Internal Medicine | 1 | 2021 | 557 | 0.14 | Why? |
| Conservative Treatment | 1 | 2018 | 349 | 0.14 | Why? |
| Medication Therapy Management | 1 | 2018 | 312 | 0.14 | Why? |
| Treatment Outcome | 8 | 2021 | 51732 | 0.14 | Why? |
| Antiphospholipid Syndrome | 1 | 2020 | 533 | 0.14 | Why? |
| Echocardiography | 3 | 2019 | 3661 | 0.13 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2018 | 604 | 0.13 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2021 | 3892 | 0.13 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 5277 | 0.13 | Why? |
| Clinical Laboratory Services | 1 | 2020 | 781 | 0.13 | Why? |
| Aged | 19 | 2021 | 215776 | 0.12 | Why? |
| Ventilation-Perfusion Ratio | 1 | 2013 | 99 | 0.12 | Why? |
| Terminology as Topic | 1 | 2018 | 546 | 0.12 | Why? |
| Heart Ventricles | 2 | 2019 | 1139 | 0.12 | Why? |
| Aortic Diseases | 1 | 2017 | 362 | 0.12 | Why? |
| Humans | 37 | 2021 | 930598 | 0.12 | Why? |
| Thyroid Crisis | 1 | 2010 | 5 | 0.11 | Why? |
| Coronary Vessels | 1 | 2019 | 914 | 0.11 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.11 | Why? |
| Posture | 1 | 2013 | 199 | 0.11 | Why? |
| Pulmonary Ventilation | 1 | 2013 | 152 | 0.11 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2018 | 830 | 0.11 | Why? |
| Perfusion Imaging | 1 | 2013 | 199 | 0.11 | Why? |
| Cerebrovascular Disorders | 1 | 2019 | 1040 | 0.11 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.10 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.10 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.09 | Why? |
| Female | 20 | 2021 | 380317 | 0.09 | Why? |
| Stroke Volume | 1 | 2018 | 2153 | 0.09 | Why? |
| Sex Factors | 3 | 2021 | 11014 | 0.09 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.08 | Why? |
| Hematologic Neoplasms | 1 | 2020 | 2105 | 0.08 | Why? |
| Prospective Studies | 7 | 2020 | 43301 | 0.08 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.08 | Why? |
| Male | 19 | 2021 | 367725 | 0.08 | Why? |
| Patient Admission | 2 | 2020 | 5250 | 0.08 | Why? |
| Acute Coronary Syndrome | 1 | 2020 | 2107 | 0.08 | Why? |
| Follow-Up Studies | 3 | 2020 | 17020 | 0.08 | Why? |
| Analysis of Variance | 2 | 2021 | 950 | 0.08 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.06 | Why? |
| Lung Diseases | 1 | 2017 | 2361 | 0.06 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2018 | 10649 | 0.06 | Why? |
| Venous Thromboembolism | 2 | 2017 | 4273 | 0.06 | Why? |
| Ambulatory Care | 1 | 2019 | 4947 | 0.06 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.05 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.05 | Why? |
| beta 2-Glycoprotein I | 1 | 2020 | 92 | 0.05 | Why? |
| Survival Rate | 3 | 2021 | 9206 | 0.05 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.05 | Why? |
| Validation Studies as Topic | 1 | 2020 | 121 | 0.05 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.05 | Why? |
| Phosphatidylserines | 1 | 2020 | 99 | 0.05 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.05 | Why? |
| Prothrombin | 1 | 2020 | 149 | 0.05 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.05 | Why? |
| Oscillometry | 1 | 2019 | 50 | 0.05 | Why? |
| Adult | 11 | 2021 | 244371 | 0.05 | Why? |
| Cross-Sectional Studies | 6 | 2021 | 53120 | 0.05 | Why? |
| Dyspnea | 1 | 2013 | 3847 | 0.05 | Why? |
| Mycoplasma pneumoniae | 1 | 2021 | 233 | 0.05 | Why? |
| Diastole | 1 | 2019 | 168 | 0.05 | Why? |
| Arterioles | 1 | 2018 | 24 | 0.05 | Why? |
| Non-Randomized Controlled Trials as Topic | 1 | 2019 | 220 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Urinalysis | 1 | 2020 | 218 | 0.05 | Why? |
| Systole | 1 | 2019 | 252 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 6653 | 0.04 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.04 | Why? |
| Hypoxia | 1 | 2013 | 3626 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2019 | 15421 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.04 | Why? |
| Aorta | 1 | 2019 | 355 | 0.04 | Why? |
| Perfusion | 1 | 2017 | 254 | 0.04 | Why? |
| Leg | 1 | 2017 | 142 | 0.04 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.04 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.04 | Why? |
| Coronary Stenosis | 1 | 2019 | 273 | 0.04 | Why? |
| Time | 1 | 2018 | 631 | 0.04 | Why? |
| Luminescent Measurements | 1 | 2020 | 924 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Cardiac Tamponade | 1 | 2018 | 165 | 0.04 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.04 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| Calcium Channel Blockers | 1 | 2017 | 367 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2019 | 9537 | 0.03 | Why? |
| Death, Sudden, Cardiac | 1 | 2018 | 522 | 0.03 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.03 | Why? |
| Nomograms | 1 | 2018 | 790 | 0.03 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| Methimazole | 1 | 2010 | 12 | 0.03 | Why? |
| Antithyroid Agents | 1 | 2010 | 28 | 0.03 | Why? |
| Ferritins | 1 | 2020 | 2055 | 0.03 | Why? |
| Metabolic Syndrome | 1 | 2019 | 810 | 0.03 | Why? |
| Bisoprolol | 1 | 2010 | 65 | 0.03 | Why? |
| Stents | 1 | 2017 | 916 | 0.02 | Why? |
| Animals | 1 | 2019 | 78931 | 0.02 | Why? |
| Coronary Angiography | 1 | 2019 | 2275 | 0.02 | Why? |
| Frailty | 1 | 2021 | 1432 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Aftercare | 1 | 2018 | 1637 | 0.02 | Why? |
| Epitopes | 1 | 2020 | 4113 | 0.02 | Why? |
| Hypertension, Pulmonary | 1 | 2017 | 970 | 0.02 | Why? |
| Muscle Weakness | 1 | 2010 | 406 | 0.02 | Why? |
| Adrenergic beta-Antagonists | 1 | 2010 | 465 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Guideline Adherence | 1 | 2019 | 2309 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Abdominal Pain | 1 | 2010 | 858 | 0.02 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Coronary Artery Disease | 1 | 2019 | 2570 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Emergencies | 1 | 2018 | 4095 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Ultrasonography | 1 | 2019 | 4409 | 0.02 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.01 | Why? |
| Venous Thrombosis | 1 | 2017 | 2739 | 0.01 | Why? |
| Myocardial Infarction | 1 | 2018 | 3361 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Registries | 1 | 2019 | 12327 | 0.01 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Anticoagulants | 1 | 2017 | 9563 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.01 | Why? |
| Lung | 1 | 2017 | 31049 | 0.01 | Why? |
| Telemedicine | 1 | 2019 | 25032 | 0.01 | Why? |
Muiesan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(202)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(180)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_